# Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo)

> **NCT03833466** · PHASE2 · UNKNOWN · sponsor: **Peking University** · enrollment: 15 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** metformin and chemotherapy

## Key facts

- **NCT ID:** NCT03833466
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-05
- **Primary completion:** 2020-03-20
- **Final completion:** 2020-06-20
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03833466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03833466, "Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03833466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*